The Defense Health Agency awarded a delivery order to Cepheid Inc. for SARS-CoV-2/Flu PCR testing supplies with a ceiling value of $880,532.90 under a firm fixed-price contract type. The delivery order, awarded on October 1, 2024, is scheduled for completion by September 30, 2025, and will support molecular diagnostic testing operations at Fort Sam Houston, Texas. This award reflects the Defense Health Agency's continued reliance on Cepheid's GeneXpert diagnostic platform and associated reagents to maintain rapid infectious disease detection capabilities across military medical facilities. No small business set-aside was utilized in this procurement.
Cepheid Inc., a Sunnyvale, California-based manufacturer of advanced molecular diagnostic systems, has established itself as a primary federal supplier of infectious disease testing solutions across multiple healthcare agencies. The company's extensive federal contracting history includes substantial indefinite delivery contracts with the Department of Veterans Affairs, including a $32.8 million contract with VISN 6 extending through 2030, and prior awards from the Indian Health Service, Defense Logistics Agency, and U.S. Coast Guard. Cepheid's core competencies encompass PCR test kits, diagnostic reagents and assays, equipment maintenance services, and cost-per-test arrangements for conditions including COVID-19, influenza, and other respiratory pathogens, positioning the company as a critical supplier to the federal healthcare procurement market.